Dabrafenib in the treatment of metastatic or unresectable melanoma (Q38364837)

2 September 2017

1 reference

title

Dabrafenib in the treatment of metastatic or unresectable melanoma (English)

1 reference

2 September 2017

Leila Khoja

1

1 reference

2 September 2017

David Hogg

series ordinal

2

1 reference

2 September 2017

publication date

1 March 2015

1 reference

Expert Review of Anticancer Therapy

2 September 2017

published in

1 reference

2 September 2017

volume

15

1 reference

2 September 2017

issue

3

1 reference

2 September 2017

page(s)

265-276

1 reference

Distinct sets of genetic alterations in melanoma

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1014343

Somatic activation of KIT in distinct subtypes of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1014343

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1014343

Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1014343

Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1014343

Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1014343

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1014343

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1014343

Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1014343

Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1014343

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1014343

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1014343

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1014343

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1014343

Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1014343

Inter- and intra-patient heterogeneity of response and progression to targeted therapy in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1014343

The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1014343

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1014343

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1014343

Hepatotoxicity with combination of vemurafenib and ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1014343

Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1014343

Features and management of pyrexia with combined dabrafenib and trametinib in metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1014343

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1014343

Paradoxical oncogenesis: are all BRAF inhibitors equal?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1014343

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1014343

Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1014343

10.1586/14737140.2015.1014343

21 January 2018

Identifiers

DOI

1 reference

2 September 2017

1 reference